These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti-CTLA-4 agents are being considered. (Funded by the Frederick Adler Fund and others.).
No takes yet. Share an insight, caveat, or question.
Snyder et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: